Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
G412950-5mg | 5mg | In stock | $127.90 | |
G412950-10mg | 10mg | In stock | $187.90 | |
G412950-25mg | 25mg | In stock | $345.90 | |
G412950-50mg | 50mg | In stock | $523.90 | |
G412950-100mg | 100mg | In stock | $791.90 |
Estrogen/progestogen Receptor Agonists
Specifications & Purity | Moligand™, ≥98% |
---|---|
Biochemical and Physiological Mechanisms | GSK5182, 4-hydroxytamoxifen analog, is a specific inverse agonist of estrogen-related receptor γ (ERRγ) that inhibits pro-inflammatory cytokine-induced catabolic factors. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST, ANTAGONIST |
Mechanism of action | Antagonist of Estrogen receptor-α;Agonist of Estrogen-related receptor-γ |
Product Description | Information GSK5182 GSK5182, 4-hydroxytamoxifen analog, is a specific inverse agonist of estrogen-related receptor γ (ERRγ) that inhibits pro-inflammatory cytokine-induced catabolic factors. Targets ERRγ |
ALogP | 5.308 |
---|---|
HBD Count | 2 |
Rotatable Bond | 10 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-5-hydroxy-2-phenylpent-1-enyl]phenol |
---|---|
INCHI | InChI=1S/C27H31NO3/c1-28(2)18-20-31-25-16-12-23(13-17-25)27(22-10-14-24(30)15-11-22)26(9-6-19-29)21-7-4-3-5-8-21/h3-5,7-8,10-17,29-30H,6,9,18-20H2,1-2H3/b27-26- |
InChi Key | ZVSFNBNLNLXEFQ-RQZHXJHFSA-N |
Canonical SMILES | CN(C)CCOC1=CC=C(C=C1)C(=C(CCCO)C2=CC=CC=C2)C3=CC=C(C=C3)O |
Isomeric SMILES | CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCO)\C2=CC=CC=C2)/C3=CC=C(C=C3)O |
PubChem CID | 6852176 |
MeSH Entry Terms | GSK5182 |
Molecular Weight | 417.54 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2313699 | Certificate of Analysis | Jun 15, 2023 | G412950 |
G2313701 | Certificate of Analysis | Jun 15, 2023 | G412950 |
G2313704 | Certificate of Analysis | Jun 15, 2023 | G412950 |
G2313706 | Certificate of Analysis | Jun 15, 2023 | G412950 |
G2313719 | Certificate of Analysis | Jun 15, 2023 | G412950 |
G2313720 | Certificate of Analysis | Jun 15, 2023 | G412950 |
G2313721 | Certificate of Analysis | Jun 15, 2023 | G412950 |
G2313724 | Certificate of Analysis | Jun 15, 2023 | G412950 |
G2313732 | Certificate of Analysis | Jun 15, 2023 | G412950 |
G2313736 | Certificate of Analysis | Jun 15, 2023 | G412950 |
Solubility | Solubility (25°C) In vitro DMSO: 84 mg/mL (201.17 mM); Ethanol: 84 mg/mL (201.17 mM); Water: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 84 |
DMSO(mM) Max Solubility | 201.178330219859 |
Water(mg / mL) Max Solubility | <1 |
1. Kim DK, Gang GT, Ryu D, Koh M, Kim YN, Kim SS, Park J, Kim YH, Sim T, Lee IK et al.. (2013) Inverse agonist of nuclear receptor ERRγ mediates antidiabetic effect through inhibition of hepatic gluconeogenesis.. Diabetes, 62 (9): (3093-102). [PMID:23775767] |